- Home
- MRSN
as 04-18-2025 1:39pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 36.4M | IPO Year: | 2017 |
| Target Price: | $4.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $3.83 | Next Earning Date: | 05-08-2025 |
| Revenue: | $40,497,000 | Revenue Growth: | 9.88% |
| Revenue Growth (this year): | -24.83% | Revenue Growth (next year): | -17.29% |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
18 days ago
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
Simply Wall St.
a month ago
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates
Simply Wall St.
a month ago
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts
Simply Wall St.
2 months ago
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
2 months ago
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Mersana Therapeutics Inc Earnings Call
Zacks
2 months ago
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.